A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score

被引:102
|
作者
Quast, Anne-Floor B. E. [1 ]
Baalman, Sarah W. E. [1 ]
Brouwer, Tom F. [1 ]
Smeding, Lonneke [1 ]
Wilde, Arthur A. M. [1 ]
Burke, Martin C. [1 ,2 ]
Knops, Reinoud E. [1 ]
机构
[1] Univ Amsterdam, Amsterdam UMC, Dept Clin & Expt Cardiol, Ctr Heart, POB 22700,Meibergdreef 9, Amsterdam, Netherlands
[2] CorVita Sci Fdn, Chicago, IL USA
关键词
Conversion testing; Defibrillation testing; Implantation; Subcutaneous implantable cardioverter-defibrillator; SHOCK IMPEDANCE; THRESHOLD; EFFICACY; OUTCOMES; SAFETY;
D O I
10.1016/j.hrthm.2018.09.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Suboptimal positioning of the subcutaneous implantable cardioverter-defibrillator (S-ICD) increases the defibrillation threshold and risk of conversion failure. OBJECTIVE Our objective is to develop a tool to evaluate the implant position and predict defibrillation success of the S-ICD: the PRAETORIAN score. METHODS The PRAETORIAN score is based on clinical and computer modeling knowledge of determinants affecting the defibrillation threshold: subcoil fat, subgenerator fat, and anterior positioning of the S-ICD generator. The score evaluates these determinants on the postoperative anterior-posterior and lateral chest radiographs and has 3 categories: 30-<90 points representing a low risk, 90-<150 points representing an intermediate risk, and >= 150 points representing a high risk of conversion failure. The score was developed using 2 separate S-ICD data sets for derivation and validation. The performance metrics are the positive and negative predictive values. RESULTS The development data set consisted of 181 patients with S-ICD, and the validation cohort consisted of 321 patients from the S-ICD Investigational Device Exemption trial. The distribution of scores was 93%-98% low risk (<90 points), 2%-5% intermediate risk (90-<150 points), and 1% high risk (>= 150 points). The positive predictive value for an intermediate or high PRAETORIAN score for a failed conversion test was 51%, while a low PRAETORIAN score predicted a successful conversion in 99.8% of patients. CONCLUSION The PRAETORIAN score allows the identification of patients with high defibrillation thresholds by using the routine chest radiograph and provides feedback to implanters on S-ICD positioning. The PRAETORIAN-DFT trial will prospectively validate the score by randomizing to standard conversion testing vs using the score without conversion testing.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 26 条
  • [21] Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable cardioverter-defibrillator
    Lloyd, Michael S.
    Brisben, Amy J.
    Reddy, Vivek Y.
    Blomstrom-Lundqvist, Carina
    Boersma, Lucas V. A.
    Bongiorni, Maria Grazia
    Burke, Martin C.
    Cantillon, Daniel J.
    Doshi, Rahul
    Friedman, Paul A.
    Gras, Daniel
    Kutalek, Steven P.
    Neuzil, Petr
    Roberts, Paul R.
    Wright, David J.
    Appl, Ursula
    West, Julie
    Carter, Nathan
    Stein, Kenneth M.
    Mont, Lluis
    Knops, Reinoud E.
    HEART RHYTHM O2, 2023, 4 (07): : 448 - 456
  • [22] Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator
    Theuns, Dominic A. M. J.
    Brouwer, Tom F.
    Jones, Paul W.
    Allavatam, Venugopal
    Donnelley, Steven
    Auricchio, Angelo
    Knops, Reinoud E.
    Burke, Martin C.
    HEART RHYTHM, 2018, 15 (10) : 1515 - 1522
  • [23] Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter- DefibrillatoR ImplANtation with and without DeFibrillation testing
    Quast, Anne-Floor B. E.
    Baalman, Sarah W. E.
    Betts, Tim R.
    Boersma, Lucas V. A.
    Bonnemeier, Hendrik
    Boveda, Serge
    Brouwer, Tom F.
    Burke, Martin C.
    Delnoy, Peter Paul H. M.
    El-Chami, Mikhael
    Kuschyk, Juergen
    Lambiase, Pier
    Marquie, Christelle
    Miller, Marc A.
    Smeding, Lonneke
    Wilde, Arthur A. M.
    Knops, Reinoud E.
    AMERICAN HEART JOURNAL, 2019, 214 : 167 - 174
  • [24] Clinical Evaluation of Defibrillation Testing in an Unselected Population of 2,120 Consecutive Patients Undergoing First Implantable Cardioverter-Defibrillator Implant
    Brignole, Michele
    Occhetta, Eraldo
    Bongiorni, Maria Grazia
    Proclemer, Alessandro
    Favale, Stefano
    Iacopino, Saverio
    Calo, Leonardo
    Vado, Antonello
    Buja, Gianfranco
    Mascioli, Giosue
    Quartieri, Fabio
    Tritto, Massimo
    Parravicini, Umberto
    Castro, Antonio
    Tomasi, Corrado
    Villani, Giovanni Quinto
    D'Acri, Matteo Giuseppe
    Klersy, Catherine
    Gasparini, Maurizio
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (11) : 981 - 987
  • [25] Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial
    Bogdan, Stefan
    Glikson, Michael
    Connolly, Stuart J.
    Wang, Jia
    Hohnloser, Stefan H.
    Appl, Ursula
    Neuzener, Jorg
    Mabo, Philippe
    Vinolas, Xavier
    Gadler, Frederick
    van Erven, Lieselot
    Kautzner, Josef
    Meeks, Brandi
    Pogue, Janice
    Healey, Jeff S.
    HEART RHYTHM, 2019, 16 (01) : 83 - 90
  • [26] Undetected displacement of a subcutaneous implantable cardioverter-defibrillator lead. importance of performing a chest X-ray during the first weeks post-implant: a case report
    Apolo, Jose
    San Antonio, Rodolfo
    Mont, Lluis
    Maria Tolosana, Jose
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2019, 3 (04)